BUSINESS

Wave of Downsizing (3): Mid-Sized Players Muted amid Industry’s Job-Shedding Drive

February 5, 2015

- Only subscribers can save articles.
  
  Sign In
  
  Subscribe

While major drug makers are pruning their payrolls globally, mid-sized players in Japan seem to be staying out of the loop. “When it comes to mid-sized drug makers, we don’t hear about voluntary retirement plans at all,” said Tadashi Suminaga…

To read the full story

Wave of Downsizing (2): Job Cuts at Non-Japanese Makers Also Come to Fore
February 4, 2015
Wave of Downsizing (1): Major Japan Drug Makers Offer Voluntary Redundancies
February 3, 2015

BUSINESS

Japan IP High Court Upholds Invalidation of Key Trazenta Dosage Patent
February 19, 2026
ONODERA GT Pharma Targets 2026 Filings for Two Gene Therapies
February 19, 2026
Sumitomo Pharma Sees iPSC Therapy as Potential US$1 Billion Global Product
February 18, 2026
AstraZeneca Launches Japan Registry Study of Imfinzi in Limited-Stage SCLC
February 18, 2026
Asahi Kasei Gets Global Rights to Alchemedicine’s Lead Compounds
February 18, 2026

Chuikyo Debate on FY2026 Drug Pricing Reform

Chuikyo OKs New CEA Handling, with Third-Party Verification Ahead

Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…

COMMENTARY

Is Calling for an Abolition the Right Play? Rethinking Japan’s FY2027 Off-Year Drug Price Revision

By Ken Yoshino

Japan’s health and finance ministers agreed late last year to go ahead with an “off-year” drug price revision in FY2027,…

COLUMN

AI in Healthcare Hiring: Leveling the Playing Field & Unlocking Human Potential

By Philip Carrigan

The Japanese healthcare sector is experiencing rapid growth, demanding a highly skilled and diverse workforce. However, finding and attracting the best talent in this competitive market presents significant challenges.Enter AI. With the rise of AI-powered tools, healthcare organizations can revolutionize…